Latano-Q (Latanoprost)

Latano‑Q is used to manage ocular conditions characterized by elevated intra‑ocular pressure.

• Open-angle glaucoma: reduces intra‑ocular pressure to help prevent progressive optic nerve damage.
• Ocular hypertension: lowers eye pressure to reduce the risk of developing glaucoma.
• Secondary open-angle glaucoma: controls pressure when glaucoma is associated with other ocular diseases.

• Latanoprost is a prostaglandin F2α analogue that binds to FP receptors in the ciliary body, stimulating remodeling of the extracellular matrix and increasing uveoscleral outflow of aqueous humor. The enhanced outflow lowers intra‑ocular pressure, thereby mitigating the primary risk factor for glaucomatous optic neuropathy. Its selective receptor activity provides sustained pressure reduction with once‑daily topical administration. The effect persists for 24 hours, allowing convenient once‑daily dosing.

Topical latanoprost may cause ocular and peri‑ocular changes, most of which are mild and reversible.

Common Side Effects

• Eye redness: mild conjunctival hyperemia that usually resolves without treatment.
• Eye irritation or burning sensation: transient discomfort after instillation.
• Increased eyelash growth on the treated eye: longer, thicker lashes may appear.
• Darkening of the iris over time: gradual increase in brown pigmentation, typically irreversible.

Serious or Rare Side Effects

• Severe eye inflammation (uveitis or iritis): may require immediate ophthalmic evaluation.
• Allergic reactions such as eyelid swelling or dermatitis: can be localized or systemic.
• Sudden loss of vision or visual field defects: rare but necessitates urgent medical attention.

When prescribing or using Latano‑Q, healthcare professionals should observe several safety considerations to minimize risks.

• Baseline assessment: measure intra‑ocular pressure before initiating therapy.
• Monitor ocular changes: schedule regular eye examinations to detect pigmentary alterations.
• Avoid use in active eye infection: postpone treatment until infection resolves.
• Caution with a history of uveitis: evaluate risk of inflammation flare.
• Pregnancy and lactation: safety not established; use only if potential benefit outweighs risk.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic or systemic agents, affecting efficacy or safety.

Major Interactions (Avoid)

• Other prostaglandin analogs: additive intra‑ocular pressure reduction may cause hypotony.
• Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): increased risk of ocular side effects.
• Topical corticosteroids: may diminish latanoprost’s pressure‑lowering effect.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory eye drops: may increase ocular irritation.
• Beta‑blocker eye drops: monitor intra‑ocular pressure for additive effect.
• Anticholinergic agents: possible influence on pupil size and accommodation.